• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经皮腔内室间隔心肌消融术与室间隔心肌切除术治疗肥厚性梗阻性心肌病患者的比较——一项荟萃分析

Comparison of percutaneous transluminal septal myocardial ablation versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy--a meta analysis.

作者信息

Zeng Zhiyu, Wang Fangzheng, Dou Xiangfeng, Zhang Shu, Pu Jielin

机构信息

Center for Arrhythmia Diagnosis and Treatment, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Int J Cardiol. 2006 Sep 10;112(1):80-4. doi: 10.1016/j.ijcard.2005.10.009. Epub 2006 Feb 28.

DOI:10.1016/j.ijcard.2005.10.009
PMID:16507323
Abstract

BACKGROUND

The effects of percutaneous transluminal septal myocardial ablation (PTSMA) with septal myectomy in patients with hypertrophic obstructive cardiomyopathy (HOCM) are not thoroughly compared.

METHODS

Three articles comparing the effects of PTSMA and septal myectomy treatment for HOCM were identified from a search in Pubmed, and a meta analysis was conducted.

RESULTS

177 patients (86 underwent PTSMA and 91 underwent septal myectomy) were included. Interventricular septum thickness was decreased from 22.1 to 15.1 mm (p<0.05) in PTSMA group and from 22.0 to 13.9 mm (p<0.05) in septal myectomy group; left ventricular end-diastolic dimension was increased from 41.8 to 45.2 mm (p<0.05) in PTSMA group and from 41.8 to 43.9 mm (p<0.05) in septal myectomy group; NYHA class was improved from 3.17 to 1.47 (p<0.05) in PTSMA group and from 2.97 to 1.36 (p<0.05) in septal myectomy group; there were no differences in the two groups. However, left ventricular outflow tract gradient was decreased from 76.0 to 15.7 mm Hg (p<0.05) in PTSMA group and from 74.7 to 9.4 mm Hg (p<0.05) in septal myectomy group and the effect of septal myectomy was better than PTSMA (p<0.05).

CONCLUSIONS

The effects of septal myectomy treatment for HOCM are better with regard to relief of LVOT gradient, and lower risk of pacemaker requirement, compared to PTSMA. Large randomized clinical trials further comparing the two treatments are suggested.

摘要

背景

肥厚性梗阻性心肌病(HOCM)患者经皮腔内室间隔心肌消融术(PTSMA)与室间隔心肌切除术的疗效尚未得到充分比较。

方法

通过检索PubMed确定了3篇比较PTSMA和室间隔心肌切除术治疗HOCM疗效的文章,并进行了荟萃分析。

结果

共纳入177例患者(86例行PTSMA,91例行室间隔心肌切除术)。PTSMA组室间隔厚度从22.1 mm降至15.1 mm(p<0.05),室间隔心肌切除术组从22.0 mm降至13.9 mm(p<0.05);PTSMA组左心室舒张末期内径从41.8 mm增加至45.2 mm(p<0.05),室间隔心肌切除术组从41.8 mm增加至43.9 mm(p<0.05);PTSMA组纽约心脏协会(NYHA)心功能分级从3.17改善至1.47(p<0.05),室间隔心肌切除术组从2.97改善至1.36(p<0.05);两组间无差异。然而,PTSMA组左心室流出道压差从76.0 mmHg降至15.7 mmHg(p<0.05),室间隔心肌切除术组从74.7 mmHg降至9.4 mmHg(p<0.05),室间隔心肌切除术的效果优于PTSMA(p<0.05)。

结论

与PTSMA相比,室间隔心肌切除术治疗HOCM在缓解左心室流出道压差方面效果更好,起搏器植入需求风险更低。建议开展进一步比较这两种治疗方法的大型随机临床试验。

相似文献

1
Comparison of percutaneous transluminal septal myocardial ablation versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy--a meta analysis.经皮腔内室间隔心肌消融术与室间隔心肌切除术治疗肥厚性梗阻性心肌病患者的比较——一项荟萃分析
Int J Cardiol. 2006 Sep 10;112(1):80-4. doi: 10.1016/j.ijcard.2005.10.009. Epub 2006 Feb 28.
2
Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery.肥厚性梗阻性心肌病患者经皮腔内室间隔心肌消融术和室间隔肌切除术术后的结局
J Am Coll Cardiol. 2001 Dec;38(7):1994-2000. doi: 10.1016/s0735-1097(01)01656-4.
3
Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets.肥厚性梗阻性心肌病合并二尖瓣前叶增大患者的经皮治疗与手术治疗对比
Circulation. 2005 Jul 26;112(4):482-8. doi: 10.1161/CIRCULATIONAHA.104.508309. Epub 2005 Jul 18.
4
Comparison of Clinical Effects between Percutaneous Transluminal Septal Myocardial Ablation and Modified Morrow Septal Myectomy on Patients with Hypertrophic Cardiomyopathy.经皮腔内室间隔心肌消融术与改良 Morrow 室间隔切除术治疗肥厚型心肌病的临床效果比较。
Chin Med J (Engl). 2018 Mar 5;131(5):527-531. doi: 10.4103/0366-6999.226075.
5
[Long-term outcome of patients with hypertrophic obstructive cardiomyopathy post percutaneous transluminal septal ablation].肥厚性梗阻性心肌病患者经皮腔内室间隔消融术后的长期预后
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Apr 24;48(4):294-301. doi: 10.3760/cma.j.cn112148-20190603-00312.
6
[Non-pharmacologic therapy of hypertrophic obstructive cardiomyopathy--results of therapy based on percutaneous transluminal septal myocardial ablation compared with results of dual-chamber cardiac pacing].肥厚性梗阻性心肌病的非药物治疗——经皮腔内室间隔心肌消融术治疗结果与双腔心脏起搏治疗结果的对比
Vnitr Lek. 2006 Apr;52(4):313-20.
7
[Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy].[经皮腔内室间隔心肌消融术治疗肥厚性梗阻性心肌病]
Zhonghua Nei Ke Za Zhi. 2006 Mar;45(3):210-2.
8
Ameliorating the severity of sleep-disordered breathing concomitant with heart failure status after percutaneous transluminal septal myocardial ablation for drug-refractory hypertrophic obstructive cardiomyopathy.经皮腔内室间隔心肌消融术治疗药物难治性肥厚性梗阻性心肌病后,改善与心力衰竭状态相关的睡眠呼吸障碍严重程度。
Heart Vessels. 2017 Nov;32(11):1320-1326. doi: 10.1007/s00380-017-0997-0. Epub 2017 May 29.
9
Successful percutaneous transluminal septal myocardial ablation through a right superior septal artery for a patient with hypertrophic obstructive cardiomyopathy.通过右上间隔动脉对肥厚型梗阻性心肌病患者成功进行经皮腔内间隔心肌消融术。
Cardiovasc Interv Ther. 2015 Oct;30(4):377-81. doi: 10.1007/s12928-014-0310-4. Epub 2014 Dec 13.
10
Percutaneous transluminal septal myocardial ablation: past, present, and future.经皮腔内室间隔心肌消融术:过去、现在和未来。
J Cardiol. 2022 Sep;80(3):211-217. doi: 10.1016/j.jjcc.2021.11.023. Epub 2021 Dec 16.

引用本文的文献

1
What are the best clinical management strategies for cardiomyopathy? an umbrella review of systematic reviews and meta-analyses.心肌病的最佳临床管理策略有哪些?系统评价和荟萃分析的综合综述。
Front Pharmacol. 2025 Jul 25;16:1544121. doi: 10.3389/fphar.2025.1544121. eCollection 2025.
2
Review of Contemporary Invasive Treatment Approaches and Critical Appraisal of Guidelines on Hypertrophic Obstructive Cardiomyopathy: State-of-the-Art Review.肥厚型梗阻性心肌病当代侵入性治疗方法综述及指南批判性评价:最新进展综述
J Clin Med. 2022 Jun 14;11(12):3405. doi: 10.3390/jcm11123405.
3
Hypertrophic cardiomyopathy.
肥厚型心肌病
Int J Cardiol Heart Vasc. 2020 Mar 25;27:100503. doi: 10.1016/j.ijcha.2020.100503. eCollection 2020 Apr.
4
Minimally Invasive Versus Full-Sternotomy Septal Myectomy for Hypertrophic Cardiomyopathy.肥厚型心肌病的微创与全胸骨切开术间隔心肌切除术对比
Innovations (Phila). 2018 Jul/Aug;13(4):261-266. doi: 10.1097/IMI.0000000000000536.
5
Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy.酒精间隔消融术治疗肥厚型梗阻性心肌病
Interv Cardiol. 2014 Apr;9(2):108-114. doi: 10.15420/icr.2011.9.2.108.
6
Hypertrophic Cardiomyopathy-Past, Present and Future.肥厚型心肌病——过去、现在与未来
J Clin Med. 2017 Dec 12;6(12):118. doi: 10.3390/jcm6120118.
7
Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.药物难治性或药物不耐受性肥厚型心肌病的起搏治疗
Cochrane Database Syst Rev. 2012 May 16;2012(5):CD008523. doi: 10.1002/14651858.CD008523.pub2.
8
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy.酒精间隔消融术治疗肥厚性梗阻性心肌病
Curr Cardiol Rev. 2008 Aug;4(3):193-7. doi: 10.2174/157340308785160561.